Dalfampridine

Active ingredient: Dalfampridine

In short: Dalfampridine Extended-Release Tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed .

Forms & strengthsDalfampridine Extended-Release Tablets are available in a 10 mg strength and is a white to off white, oval shaped, biconvex, film coated tablets, debossed with “FH6” on one side and plain on other side.
LabelAccord Healthcare Inc.
Label updatedNov 09, 2026

What is Dalfampridine used for?

Dalfampridine Extended-Release Tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed

.

Dalfampridine dosage

The maximum recommended dosage of Dalfampridine Extended-Release Tablet is one 10 mg tablet twice daily and should not be exceeded. Take doses approximately 12 hours apart.

There is no evidence of additional benefit at doses greater than 10 mg twice daily. Adverse reactions, including seizures, and discontinuations because of adverse reactions were more frequent at higher doses.

Dalfampridine Extended-Release Tablets can be taken with or without food. Administer tablets whole; do not divide, crush, chew, or dissolve Dalfampridine Extended-Release Tablets.

If a dose is missed, patients should not take double or extra doses.

Estimated creatinine clearance (CrCl) should be known before initiating treatment with Dalfampridine Extended-Release Tablets, and monitored at least annually during treatment with Dalfampridine Extended-Release Tablets. CrCl can be estimated using the following equation (multiply by 0.85 for women):

CrCl = | (140 -

age) ×

weight(

kg)

SerumCr(

mg/

dl)× 72

In patients with mild renal impairment (CrCl 51 to 80 mL/min), Dalfampridine Extended-Release Tablets plasma levels may approach those seen at a dose of 15 mg twice daily, a dose that is 1.5 times the maximum recommended dose and may be associated with an increased risk of seizures. As mild renal impairment is common after age 50, estimating CrCl is particularly important in these patients. The potential benefits of Dalfampridine Extended-Release Tablets should be carefully considered against the risk of seizures in these patients

.

Dalfampridine Extended-Release Tablets are contraindicated in patients with moderate or severe renal impairment (CrCl≤50 mL/min).

How to take Dalfampridine — instructions & advice from the label

Advise the patient to read the

FDA-approved patient labeling (Medication Guide).

Risk of Seizures

Inform patients that Dalfampridine Extended-Release Tablets can cause seizures, and that they must discontinue use of Dalfampridine Extended-Release Tablets if they experience a seizure

.

Dalfampridine Extended-Release Tablets dosing

Instruct patients to take Dalfampridine Extended-Release Tablets exactly as prescribed. Instruct patients not to take a double dose after they miss a dose, as this would increase their risk of seizure. Instruct patients not to take more than 2 tablets in a 24-hour period and to make sure that there is an approximate 12-hour interval between doses

.

Anaphylaxis

Advise patients to discontinue Dalfampridine Extended-Release Tablets and seek medical care if they develop signs and symptoms of anaphylaxis

.

Effects on Driving or Using Machinery

Counsel patients that central nervous system-related adverse reactions, such as vertigo and dizziness, associated with the use of Dalfampridine Extended-Release Tablets might impair their ability to drive or use machinery should they develop these symptoms. …

Warnings & precautions

Do not take this medicine if: The use of Dalfampridine Extended-Release Tablets are contraindicated in the following conditions:

History of seizure

Moderate or severe renal impairment (CrCl≤50 mL/min)

History of hypersensitivity to dalfampridine or 4-aminopyridine; reactions have included anaphylaxis

Dalfampridine can cause seizures. Increased incidence of seizures has been observed at 20 mg twice daily (2 times the maximum recommended dosage) in controlled clinical studies of 9 to 14 weeks duration with Dalfampridine Extended-Release Tablets in patients with MS. In open-label extension trials in MS patients, the incidence of seizures during treatment with Dalfampridine Extended-Release Tablets 15 mg twice daily (1.7/100PY) was over 4 times higher than the incidence during treatment with 10 mg twice daily (0.4/100PY). In the post-marketing period seizures have been reported. The majority of seizures occurred at the recommended dose and in patients without a history of seizures, and generally within days to weeks of starting therapy.

Dalfampridine Extended-Release Tablets have not been evaluated in patients with a history of seizures or with evidence of epileptiform activity on an EEG, as these patients were excluded from clinical trials. The risk of seizures in patients with epileptiform activity on an EEG is unknown, and could be substantially higher than that observed in Dalfampridine Extended-Release Tablets clinical studies. Permanently discontinue Dalfampridine Extended-Release Tablets in patients who experience have a seizure while on treatment. Dalfampridine Extended-Release Tablets are contraindicated in patients with a history of seizures

.

Dalfampridine is eliminated through the kidneys primarily as unchanged drug

. …

Dalfampridine side effects

The following serious adverse reactions are described in more detail elsewhere in the labeling:

Seizures

Anaphylaxis

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

In three placebo-controlled clinical trials of up to 14 weeks duration, 4% (15/400) of patients treated with Dalfampridine Extended-Release Tablets 10 mg twice daily experienced one or more adverse reactions leading to discontinuation, compared to 2% (5/238) of placebo-treated patients. The adverse reactions leading to discontinuation of at least 2 patients treated with Dalfampridine Extended-Release Tablets and that led to discontinuation more frequently compared to placebo were headache (Dalfampridine Extended-Release Tablets 0.5%, placebo 0%), balance disorder (Dalfampridine Extended-Release Tablets 0.5%, placebo 0%), dizziness (Dalfampridine Extended-Release Tablets 0.5%, placebo 0%), and confusional state (Dalfampridine Extended-Release Tablets 0.3%, placebo 0%).

Table 1 lists adverse reactions that occurred in ≥2% of patients treated with Dalfampridine Extended-Release Tablets 10 mg twice daily, and more frequently than in placebo-treated patients, in controlled clinical trials. …

Drug interactions

Concurrent treatment with OCT2 inhibitors, such as cimetidine, may cause increased exposure to dalfampridine

. Elevated levels of dalfampridine increase the risk of seizures

.

The potential benefits of taking OCT2 inhibitors concurrently with Dalfampridine Extended-Release Tablets should be considered against the risk of seizures in these patients.

No interaction was identified between dalfampridine and baclofen

.

About this medicine

Dalfampridine is a potassium channel blocker, available in a 10 mg tablet strength. Each tablet contains 10 mg dalfampridine, formulated as an extended-release tablet for twice-daily oral administration. Dalfampridine is also known by its chemical name, 4-aminopyridine, with the following structure:

Dalfampridine Extended-Release Tablets are available in a 10 mg strength and are white to off white, oval shaped, biconvex, film-coated, tablets, debossed with "FH6" on one side and plain on other side, containing 10 mg of dalfampridine. Inactive ingredients consist of colloidal anhydrous silica, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.

Dalfampridine is a fine white powder with a molecular weight of 94.1, CAS 504-24-5, and a molecular formula of C

5H

6N

2. At ambient conditions, dalfampridine is soluble in water, methanol, acetone, tetrahydrofuran, isopropanol, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, and ethanol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 354a97e8-35c8-418b-91b2-9e8e066cec65. Read the full official label on DailyMed.